The Indianapolis-based company said it had net income of $1.81 per share. Earnings, adjusted for one-time gains and costs, came to $3.84 per share. The results beat Wall Street expectations. The average estimate of 17 analysts surveyed by Zacks Investment Research was for earnings of $3.80 per share.

Elevance Health released fourth-quarter earnings that topped analyst expectations, sending its stock higher in pre-market trading Thursday. Shares of Elevance gained more than 4% to $408 a share before the bell.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a high estimate of $512.00 and a low estimate of $478.00. A decline of 6.69% from the prior average price target is evident in the current average.

Elevance Health's board has raised the health insurer and healthcare-services provider's quarterly dividend by 4.9%, to $1.71 from $1.63. The new payout, equal to $6.84 a year, represents an annual yield of about 1.75%, based on Wednesday's closing price of $390.73, up from 1.67%.

Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting."

Elevance Health Inc.’s stock jumped 5% in premarket trade Thursday and boosted other health insurance stocks, after the company delivered better-than-expected earnings and forecast growth for 2025, easing investor concerns after a big miss in the third quarter.

Elevance executives talked about the cost trend environment for employer health plans Thursday, during a conference call with securities analysts. The Indianapolis-based health insurer and health ...

Shares of Elevance Health Inc. ELV slipped 1.42% to $405.40 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.92% to 6,067.70 and the Dow Jones Industrial Average DJIA rising 0.31% to 44,850.35.

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

Elevance Health Inc.'s stock rose 2% Thursday and ... Medicaid business following the recent re-eligibility checks." The Indianapolis-based company (ELV) had net income of $413 million, or $1 ...